Wanbury Limited has informed the Exchange regarding a press release dated March 24, 2026, titled "Wanbury Strengthens Coriminic Brand with Pediatric-Focused, Regulation-Aligned Launches".

Regulatory Product ApprovalBusiness Updates View source PDF

WANBURY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.0%1-day move

₹235.90

prior close

₹241.15

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.5+0.5-0.5+0.0-1.0-4.2-5.1-2.3-1.7-4.6+11.6+9.6+21.2+18.6

Up moveDown movePending

AI summary

Wanbury Limited has launched two new pediatric products under its well-known Coriminic brand: Coriminic CPM Drops (Chlorpheniramine Maleate without decongestant) and Coriminic NS Normal Saline Nasal Drops. The launches are designed to comply with recent DCGI restrictions limiting fixed-dose combinations of Chlorpheniramine + Phenylephrine in children below 4 years due to safety concerns. The company is targeting the ₹861 crore Cold Preparation Liquid market with these regulation-aligned products. Wanbury describes this as a first-of-its-kind India-focused initiative to reposition Chlorpheniramine in a safer, indication-driven format for children.

Likely market impact

This is a strategic product expansion that could help Wanbury capture market share in the pediatric cold segment by offering regulation-compliant alternatives. Positive for the brand's positioning and potential revenue growth, though no specific revenue guidance or financial impact was provided.